In the relentless pursuit of effective cancer treatments, the precise synthesis of complex molecules is paramount. At NINGBO INNO PHARMCHEM CO.,LTD., we understand the critical importance of high-quality pharmaceutical intermediates. One such vital compound is 4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline, identified by its CAS number 183322-18-1. This fine chemical serves as an indispensable building block in the development of advanced oncology drugs, offering significant potential in targeted therapies.

The significance of 4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline lies in its role as an intermediate for Erlotinib hydrochloride, a well-known epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used to treat certain types of non-small cell lung cancer and pancreatic cancer. As a leading pharmaceutical intermediate manufacturer in China, NINGBO INNO PHARMCHEM CO.,LTD. is dedicated to supplying this compound with exceptional purity and consistency. Our commitment to quality ensures that researchers and pharmaceutical companies have access to a reliable source for their critical API synthesis needs.

Beyond its application in Erlotinib synthesis, 4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline exhibits biological activity as an Aurora 2 kinase inhibitor and a PDGF inhibitor. These properties make it a valuable asset in the research and development of novel anti-cancer agents that target specific cellular pathways involved in tumor growth and proliferation. The demand for such high-performance intermediates is steadily increasing as the pharmaceutical industry pushes the boundaries of medical innovation. Understanding the intricate processes of Erlotinib intermediate synthesis is key to unlocking new treatment modalities.

For organizations seeking a dependable supplier of high purity fine chemicals, NINGBO INNO PHARMCHEM CO.,LTD. offers a robust solution. We pride ourselves on our stringent quality control measures and our ability to meet the diverse requirements of the global pharmaceutical market. Whether you are in the early stages of drug discovery or scaling up production, our commitment to excellence ensures that you receive products that adhere to the highest industry standards. The availability of this compound is crucial for advancing cancer research and developing more effective treatments, underscoring the importance of a reliable pharmaceutical intermediate provider.

In summary, 4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline (CAS 183322-18-1) is more than just a chemical compound; it is a cornerstone in the development of targeted cancer therapies. NINGBO INNO PHARMCHEM CO.,LTD. is proud to be a key player in this field, providing the essential intermediates that power pharmaceutical innovation. We invite you to partner with us for your chemical needs and contribute to the future of medicine.